A U.S. start-up has entered the race to commercialise CRISPR. By using “base editing,” the company hope to treat some of the most devastating genetic disorders.
Altering the genome, typically to better understand gene and protein function. This also paves the way for gene therapy.
There are fears that CRISPR could be used by criminals to clear their names from forensic databases or evade detection, as access to the technique becomes more widely available.
The gene atlas enables a new functional view on how we study the human genome, and provides a tool that will change how we study and treat cancer and genetic disorders.
Researchers have discovered a way to greatly improve the accuracy of gene-editing technology by replacing the natural guide molecule it uses with a synthetic one called a bridged nucleic acid, or BNA.
Artificial human embryos could soon be on the horizon, but what will it mean? Well, arguably the potential of such a breakthrough could herald a new biological revolution.
Studies using CRISPR on monkeys look encouraging, but more needs to be done before the gene-editing technology can be used on humans.
Researchers have tweaked CRISPR, enabling them to monitor the outcome of tens of thousands of gene edits in the time it currently takes to analyse a few.
Experts in medicine and law are urging the US to allow for the replacement of mutation-bearing mitochondria to prevent fatal illnesses in children.